Akcea Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year Three
Akcea Therapeutics, Inc. had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $5.86 million as of 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2020-08-05
- 2020-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $5.86M.
- 2020-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $5.86M.
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $5.86M.
- 2019-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $5.86M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Three |
|---|---|
| 2020-06-30 | $5.86M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $5.86M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.86M 10-K · filed 2020-03-02 |
| 2019-09-30 | $5.86M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $5.86M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $5.86M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $5.86M 10-K · filed 2019-03-01 |